Fig. 1

The cumulative incidence of HBeAg seroclearance in HBeAg-positive patients treated with nucleos(t)ide analogues by Kaplan-Meier analysis and log-rank test. (A) Comparison between patients with and without hepatic steatosis in overall population (N = 196). The 5-year cumulative incidence of HBeAg seroconversion was 62.8 and 67.7%, respectively (p = 0.398). (B) Comparison between patients with and without hepatic steatosis in age- and gender-matched subgroups (N = 112). The 5-year cumulative incidence of HBeAg seroclearance was 62.4 and 66.9%, respectively (p = 0.395)